← Trials/Trial dossier/NCT03693430

STEP 5

CompletedPhase 3Results posted

Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity

Two-year Effect and Safety of Semaglutide 2.4 mg Once-weekly in Subjects With Overweight or Obesity

Lead sponsor

Novo Nordisk A/S

Asset

Semaglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

304

actual

Study population

Obesity / overweight

Key I/E criterion

—

Primary endpoints

•Body weight, % change•≥5% weight-loss responders

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT03693430

Org study IDNN9536-4378

Secondary ID2017-003726-32European Medicines Agency (EudraCT)

Secondary IDU1111-1202-1740World Health Organization (WHO)

Timeline

Milestones

Study first posted2018-10-03actual

Study start2018-10-05actual

Primary completion2021-01-29actual

Study completion2021-03-23actual

Results first posted2022-03-23actual

Last update posted2023-07-06actual

Assets

Investigational agents

Semaglutide

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Male or female, age more than or equal to 18 years at the time of signing informed consent

•Body mass index (BMI) more than or equal to 30 kg/m^2 or more than or equal to 27 kg/m^2 with the presence of at least one of the following weight-related comorbidities (treated or untreated): hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease

•History of at least one self-reported unsuccessful dietary effort to lose body weight

Exclusion criteria

•HbA1c more than or equal to 48 mmol/mol (6.5%) as measured by the central laboratory at screening

•A self-reported change in body weight more than 5 kg (11 lbs) within 90 days before screening irrespective of medical records

Endpoints (74)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition

Cardiometabolic biomarkers

Glycemic / diabetes

Safety / tolerability / PK

Weight & body composition

32 endpoints

Primary/registry result

Percentage Change From Baseline (Week 0) to Week 104 in Body Weight

Time frame:From Baseline (Week 0) to Week 104

Body weight, % change

percent change from baseline, improvement

Posted result

Group	Value (mean), percentage change	95% CI
Semaglutide 2.4 mgIn-trial observation period	-15.9	—
On-treatment observation period	-17.3	—
PlaceboIn-trial observation period	-1.9	—
On-treatment observation period	-2.0	—

Treatment difference-12.5595% CI-15.33 – -9.77p<.0001ANCOVA

Treatment policy estimand

Treatment difference-16.0595% CI-18.64 – -13.45p<0.0001MMRM (Mixed model repeated measurement)

Hypothetical estimand

Primary/registry result

Number of Participants Who Achieved (Yes/no): Body Weight Reduction More Than or Equal to 5%

Time frame:At Week 104

≥5% weight-loss responders

threshold achievement, improvement

Posted result

Group	Value (count_of_participants), Participants	95% CI
Semaglutide 2.4 mgIn-trial observation period	111	—
In-trial observation period	33	—
On-treatment observation period	110	—
On-treatment observation period	22	—
PlaceboIn-trial observation period	44	—
In-trial observation period	84	—
On-treatment observation period	38	—
On-treatment observation period	71	—

Odds Ratio (OR)4.9995% CI2.95 – 8.42p<0.0001Regression, Logistic

Treatment policy estimand

Odds Ratio (OR)18.0695% CI10.04 – 32.49p<0.0001MMRM

Hypothetical estimand

Primary/protocol endpoint

Percentage Change From Baseline (Week 0) to Week 104 in Body Weight

Time frame:From Baseline (Week 0) to Week 104

Body weight, % change

percent change from baseline, improvement

Primary/protocol endpoint

Number of Participants Who Achieved (Yes/no): Body Weight Reduction More Than or Equal to 5%

Time frame:At Week 104

≥5% weight-loss responders

threshold achievement, improvement

Secondary/registry result

Number of Participants Who Achieved (Yes/no): Body Weight Reduction More Than or Equal to 10%

Time frame:At Week 104

≥10% weight-loss responders

threshold achievement, improvement

Posted result

Group	Value (count_of_participants), Participants	95% CI
Semaglutide 2.4 mg	89	—
	55	—
Placebo	17	—
	111	—

Secondary/registry result

Number of Participants Who Achieved (Yes/no): Body Weight Reduction More Than or Equal to 15%

Time frame:At Week 104

≥15% weight-loss responders

threshold achievement, improvement

Posted result

Group	Value (count_of_participants), Participants	95% CI
Semaglutide 2.4 mg	75	—
	69	—
Placebo	9	—
	119	—

Secondary/registry result

Number of Participants Who Achieved (Yes/no): Body Weight Reduction More Than or Equal to 20%

Time frame:At Week 104

≥20% weight-loss responders

threshold achievement, improvement

Posted result

Group	Value (count_of_participants), Participants	95% CI
Semaglutide 2.4 mg	52	—
	92	—
Placebo	3	—
	125	—

Secondary/registry result

Change From Baseline (Week 0) to Week 104 in Waist Circumference

Time frame:From Baseline (Week 0) to Week 104

Waist circumference, change

change from baseline, improvement

Posted result

Group	Value (mean), centimeter (cm)	95% CI
Semaglutide 2.4 mg	-15.2	—
Placebo	-4.3	—

Secondary/registry result

Change From Baseline (Week 0) to Week 104 in Body Weight (kg)

Time frame:From Baseline (Week 0) to Week 104

Body weight, absolute change (kg)

change from baseline, improvement

Posted result

Group	Value (mean), kilogram	95% CI
Semaglutide 2.4 mg	-16.9	—
Placebo	-2.1	—

Secondary/registry result

Change From Baseline (Week 0) to Week 104 in Body Mass Index (BMI)

Time frame:From Baseline (Week 0) to Week 104

BMI, change

change from baseline, improvement

Posted result

Group	Value (mean), kilogram per square meter (kg/m^2)	95% CI
Semaglutide 2.4 mg	-6.2	—
Placebo	-0.7	—

Secondary/registry result

Percentage Change From Baseline (Week 0) to Week 52 in Body Weight

Time frame:From Baseline (Week 0) to Week 52

Body weight, % change

percent change from baseline, improvement

Posted result

Group	Value (mean), percentage change	95% CI
Semaglutide 2.4 mg	-15.8	—
Placebo	-3.3	—

Secondary/registry result

Change From Baseline (Week 0) to Week 52 in Body Weight (kg)

Time frame:From Baseline (Week 0) to Week 52

Body weight, absolute change (kg)

change from baseline, improvement

Posted result

Group	Value (mean), kilogram (kg)	95% CI
Semaglutide 2.4 mg	-16.7	—
Placebo	-3.5	—

Secondary/registry result

Change From Baseline (Week 0) to Week 52 in Body Mass Index (BMI)

Time frame:From Baseline (Week 0) to Week 52

BMI, change

change from baseline, improvement

Posted result

Group	Value (mean), kilogram per square meter (kg/m^2)	95% CI
Semaglutide 2.4 mg	-6.1	—
Placebo	-1.3	—

Secondary/registry result

Change From Baseline (Week 0) to Week 52 in Waist Circumference

Time frame:From Baseline (Week 0) to Week 52

Waist circumference, change

change from baseline, improvement

Posted result

Group	Value (mean), centimeter (cm)	95% CI
Semaglutide 2.4 mg	-14.3	—
Placebo	-4.5	—

Secondary/registry result

Number of Participants Who at 52 Weeks Achieved (Yes/no): Body Weight Reduction More Than or Equal to 5%

Time frame:At Week 52

≥5% weight-loss responders

threshold achievement, improvement

Posted result

Group	Value (count_of_participants), Participants	95% CI
Semaglutide 2.4 mg	132	—
	17	—
Placebo	38	—
	91	—

Secondary/registry result

Number of Participants Who at 52 Weeks Achieved (Yes/no): Body Weight Reduction More Than or Equal to 10%

Time frame:At Week 52

≥10% weight-loss responders

threshold achievement, improvement

Posted result

Group	Value (count_of_participants), Participants	95% CI
Semaglutide 2.4 mg	102	—
	47	—
Placebo	17	—
	112	—

Secondary/registry result

Number of Participants Who at 52 Weeks Achieved (Yes/no): Body Weight Reduction More Than or Equal to 15%

Time frame:At Week 52

≥15% weight-loss responders

threshold achievement, improvement

Posted result

Group	Value (count_of_participants), Participants	95% CI
Semaglutide 2.4 mg	78	—
	71	—
Placebo	7	—
	122	—

Secondary/registry result

Number of Participants Who at 52 Weeks Achieved (Yes/no): Body Weight Reduction More Than or Equal to 20%

Time frame:At Week 52

≥20% weight-loss responders

threshold achievement, improvement

Posted result

Group	Value (count_of_participants), Participants	95% CI
Semaglutide 2.4 mg	52	—
	97	—
Placebo	3	—
	126	—

Secondary/protocol endpoint

Number of Participants Who Achieved (Yes/no): Body Weight Reduction More Than or Equal to 10%

Time frame:At Week 104

≥10% weight-loss responders

threshold achievement, improvement

Secondary/protocol endpoint

Number of Participants Who Achieved (Yes/no): Body Weight Reduction More Than or Equal to 15%

Time frame:At Week 104

≥15% weight-loss responders

threshold achievement, improvement

Secondary/protocol endpoint

Number of Participants Who Achieved (Yes/no): Body Weight Reduction More Than or Equal to 20%

Time frame:At Week 104

≥20% weight-loss responders

threshold achievement, improvement

Secondary/protocol endpoint

Change From Baseline (Week 0) to Week 104 in Waist Circumference

Time frame:From Baseline (Week 0) to Week 104

Waist circumference, change

change from baseline, improvement

Secondary/protocol endpoint

Change From Baseline (Week 0) to Week 104 in Body Weight (kg)

Time frame:From Baseline (Week 0) to Week 104

Body weight, absolute change (kg)

change from baseline, improvement

Secondary/protocol endpoint

Change From Baseline (Week 0) to Week 104 in Body Mass Index (BMI)

Time frame:From Baseline (Week 0) to Week 104

BMI, change

change from baseline, improvement

Secondary/protocol endpoint

Percentage Change From Baseline (Week 0) to Week 52 in Body Weight

Time frame:From Baseline (Week 0) to Week 52

Body weight, % change

percent change from baseline, improvement

Secondary/protocol endpoint

Change From Baseline (Week 0) to Week 52 in Body Weight (kg)

Time frame:From Baseline (Week 0) to Week 52

Body weight, absolute change (kg)

change from baseline, improvement

Secondary/protocol endpoint

Change From Baseline (Week 0) to Week 52 in Body Mass Index (BMI)

Time frame:From Baseline (Week 0) to Week 52

BMI, change

change from baseline, improvement

Secondary/protocol endpoint

Change From Baseline (Week 0) to Week 52 in Waist Circumference

Time frame:From Baseline (Week 0) to Week 52

Waist circumference, change

change from baseline, improvement

Secondary/protocol endpoint

Number of Participants Who at 52 Weeks Achieved (Yes/no): Body Weight Reduction More Than or Equal to 5%

Time frame:At Week 52

≥5% weight-loss responders

threshold achievement, improvement

Secondary/protocol endpoint

Number of Participants Who at 52 Weeks Achieved (Yes/no): Body Weight Reduction More Than or Equal to 10%

Time frame:At Week 52

≥10% weight-loss responders

threshold achievement, improvement

Secondary/protocol endpoint

Number of Participants Who at 52 Weeks Achieved (Yes/no): Body Weight Reduction More Than or Equal to 15%

Time frame:At Week 52

≥15% weight-loss responders

threshold achievement, improvement

Secondary/protocol endpoint

Number of Participants Who at 52 Weeks Achieved (Yes/no): Body Weight Reduction More Than or Equal to 20%

Time frame:At Week 52

≥20% weight-loss responders

threshold achievement, improvement

Glycemic / diabetes

12 endpoints

Secondary/registry result

Change in Glycated Haemoglobin (HbA1c) (Percent [%])

Time frame:From Baseline (Week 0) to Week 104

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Posted result

Group	Value (mean), Percent of glycated haemoglobin	95% CI
Semaglutide 2.4 mg	-0.5	—
Placebo	-0.1	—

Secondary/registry result

Change From Baseline (Week 0) to Week 104 in HbA1c (mmol/Mol)

Time frame:From Baseline (Week 0) to Week 104

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Posted result

Group	Value (mean), mmol/mol	95% CI
Semaglutide 2.4 mg	-5.1	—
Placebo	-1.0	—

Secondary/registry result

Change From Baseline (Week 0) to Week 104 in Fasting Plasma Glucose (FPG) (mmol/L)

Time frame:From Baseline (Week 0) to Week 104

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Posted result

Group	Value (mean), mmol/L	95% CI
Semaglutide 2.4 mg	-0.5	—
Placebo	0.1	—

Secondary/registry result

Change From Baseline (Week 0) to Week 104 in FPG (mg/dL)

Time frame:From Baseline (Week 0) to Week 104

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Posted result

Group	Value (mean), mg/dL	95% CI
Semaglutide 2.4 mg	-8.3	—
Placebo	1.8	—

Secondary/registry result

Change in Fasting Serum Insulin-ratio to Baseline (Pmol/L)

Time frame:From Baseline (Week 0) to Week 104

ratio, improvement

Posted result

Group	Value (geometric_mean), Ratio of fasting serum insulin	95% CI
Semaglutide 2.4 mg	0.68	—
Placebo	0.96	—

Secondary/registry result

Change in Fasting Serum Insulin-ratio to Baseline (mIU/mL)

Time frame:From Baseline (Week 0) to Week 104

ratio, improvement

Posted result

Group	Value (geometric_mean), Ratio of fasting serum insulin	95% CI
Semaglutide 2.4 mg	0.68	—
Placebo	0.96	—

Secondary/protocol endpoint

Change in Glycated Haemoglobin (HbA1c) (Percent [%])

Time frame:From Baseline (Week 0) to Week 104

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Secondary/protocol endpoint

Change From Baseline (Week 0) to Week 104 in HbA1c (mmol/Mol)

Time frame:From Baseline (Week 0) to Week 104

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Secondary/protocol endpoint

Change From Baseline (Week 0) to Week 104 in Fasting Plasma Glucose (FPG) (mmol/L)

Time frame:From Baseline (Week 0) to Week 104

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Secondary/protocol endpoint

Change From Baseline (Week 0) to Week 104 in FPG (mg/dL)

Time frame:From Baseline (Week 0) to Week 104

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Secondary/protocol endpoint/low confidence

Change in Fasting Serum Insulin-ratio to Baseline (Pmol/L)

Time frame:From Baseline (Week 0) to Week 104

ratio, improvement

Secondary/protocol endpoint

Change in Fasting Serum Insulin-ratio to Baseline (mIU/mL)

Time frame:From Baseline (Week 0) to Week 104

ratio, improvement

Cardiometabolic biomarkers

20 endpoints

Secondary/registry result

Change From Baseline (Week 0) to Week 104 in Systolic Blood Pressure

Time frame:From Baseline (Week 0) to Week 104

Systolic BP, change

change from baseline, improvement

LOINC 8480-6

Posted result

Group	Value (mean), millimeter of mercury (mmHg)	95% CI
Semaglutide 2.4 mg	-6	—
Placebo	-1	—

Secondary/registry result

Change From Baseline (Week 0) to Week 104 in Diastolic Blood Pressure

Time frame:From Baseline (Week 0) to Week 104

Diastolic BP, change

change from baseline, improvement

LOINC 8462-4

Posted result

Group	Value (mean), mmHg	95% CI
Semaglutide 2.4 mg	-4	—
Placebo	-1	—

Secondary/registry result

Change in Total Cholesterol-ratio to Baseline

Time frame:From Baseline (Week 0) to Week 104

Total cholesterol, change

ratio, improvement

LOINC 2093-3

Posted result

Group	Value (geometric_mean), Ratio of total cholesterol	95% CI
Semaglutide 2.4 mg	0.96	—
Placebo	1.02	—

Secondary/registry result

Change in High Density Lipoprotein (HDL) Cholesterol-ratio to Baseline

Time frame:From Baseline (Week 0) to Week 104

HDL-C, change

ratio, improvement

LOINC 2085-9

Posted result

Group	Value (geometric_mean), Ratio of HDL cholesterol	95% CI
Semaglutide 2.4 mg	1.09	—
Placebo	1.08	—

Secondary/registry result

Change in Low Density Lipoprotein (LDL) Cholesterol-ratio to Baseline

Time frame:From Baseline (Week 0) to Week 104

LDL-C, change

ratio, improvement

LOINC 13457-7

Posted result

Group	Value (geometric_mean), Ratio of LDL cholesterol	95% CI
Semaglutide 2.4 mg	0.93	—
Placebo	0.99	—

Secondary/registry result

Change in Very Low Density Lipoprotein (VLDL) Cholesterol-ratio to Baseline

Time frame:From Baseline (Week 0) to Week 104

VLDL, change

ratio, improvement

Posted result

Group	Value (geometric_mean), Ratio of VLDL cholesterol	95% CI
Semaglutide 2.4 mg	0.79	—
Placebo	1.03	—

Secondary/registry result

Change in Free Fatty Acids-ratio to Baseline

Time frame:From Baseline (Week 0) to Week 104

Free fatty acids, change

ratio, improvement

Posted result

Group	Value (geometric_mean), Ratio of free fatty acids	95% CI
Semaglutide 2.4 mg	0.99	—
Placebo	1.07	—

Secondary/registry result

Change in Triglycerides-ratio to Baseline

Time frame:From Baseline (Week 0) to Week 104

Triglycerides, change

ratio, improvement

LOINC 2571-8

Posted result

Group	Value (geometric_mean), Ratio of triglycerides	95% CI
Semaglutide 2.4 mg	0.79	—
Placebo	1.03	—

Secondary/registry result

Change in High Sensitivity C-reactive Protein (hsCRP)-Ratio to Baseline

Time frame:From Baseline (Week 0) to Week 104

hs-CRP, change

ratio, improvement

LOINC 30522-7

Posted result

Group	Value (geometric_mean), Ratio of hsCRP	95% CI
Semaglutide 2.4 mg	0.41	—
Placebo	0.99	—

Secondary/registry result

Change From Baseline (Week 0) to Week 104 in Pulse

Time frame:From Baseline (Week 0) to Week 104

Heart rate, change

change from baseline, improvement

Posted result

Group	Value (mean), beats per minute (beats/min)	95% CI
Semaglutide 2.4 mg	3	—
Placebo	-1	—

Secondary/protocol endpoint

Change From Baseline (Week 0) to Week 104 in Systolic Blood Pressure

Time frame:From Baseline (Week 0) to Week 104

Systolic BP, change

change from baseline, improvement

LOINC 8480-6

Secondary/protocol endpoint

Change From Baseline (Week 0) to Week 104 in Diastolic Blood Pressure

Time frame:From Baseline (Week 0) to Week 104

Diastolic BP, change

change from baseline, improvement

LOINC 8462-4

Secondary/protocol endpoint

Change in Total Cholesterol-ratio to Baseline

Time frame:From Baseline (Week 0) to Week 104

Total cholesterol, change

ratio, improvement

LOINC 2093-3

Secondary/protocol endpoint

Change in High Density Lipoprotein (HDL) Cholesterol-ratio to Baseline

Time frame:From Baseline (Week 0) to Week 104

HDL-C, change

ratio, improvement

LOINC 2085-9

Secondary/protocol endpoint

Change in Low Density Lipoprotein (LDL) Cholesterol-ratio to Baseline

Time frame:From Baseline (Week 0) to Week 104

LDL-C, change

ratio, improvement

LOINC 13457-7

Secondary/protocol endpoint

Change in Very Low Density Lipoprotein (VLDL) Cholesterol-ratio to Baseline

Time frame:From Baseline (Week 0) to Week 104

VLDL, change

ratio, improvement

Secondary/protocol endpoint

Change in Free Fatty Acids-ratio to Baseline

Time frame:From Baseline (Week 0) to Week 104

Free fatty acids, change

ratio, improvement

Secondary/protocol endpoint

Change in Triglycerides-ratio to Baseline

Time frame:From Baseline (Week 0) to Week 104

Triglycerides, change

ratio, improvement

LOINC 2571-8

Secondary/protocol endpoint

Change in High Sensitivity C-reactive Protein (hsCRP)-Ratio to Baseline

Time frame:From Baseline (Week 0) to Week 104

hs-CRP, change

ratio, improvement

LOINC 30522-7

Secondary/protocol endpoint

Change From Baseline (Week 0) to Week 104 in Pulse

Time frame:From Baseline (Week 0) to Week 104

Heart rate, change

change from baseline, improvement

Safety / tolerability / PK

10 endpoints

Secondary/registry result

Number of Treatment-emergent Adverse Events (TEAEs)

Time frame:From Baseline (Week 0) to Week 111

Treatment-emergent AEs (any)

event count, event

Posted result

Group	Value (number), events	95% CI
Semaglutide 2.4 mg	1645	—
Placebo	1059	—

Secondary/registry result

Number of Serious Adverse Events (SAEs)

Time frame:From Baseline (Week 0) to Week 111

Serious AEs (any)

event count, event

Posted result

Group	Value (number), events	95% CI
Semaglutide 2.4 mg	18	—
Placebo	20	—

Secondary/registry result

Change From Baseline (Week 0) to Week 104 in Amylase

Time frame:From Baseline (Week 0) to Week 104

change from baseline, descriptive

Posted result

Group	Value (geometric_mean), Units/liter (U/L)	95% CI
Semaglutide 2.4 mg	1.13	—
Placebo	1.02	—

Secondary/registry result

Change From Baseline (Week 0) to Week 104 in Lipase

Time frame:From Baseline (Week 0) to Week 104

change from baseline, descriptive

Posted result

Group	Value (geometric_mean), U/L	95% CI
Semaglutide 2.4 mg	1.47	—
Placebo	1.00	—

Secondary/registry result

Change From Baseline (Week 0) to Week 104 in Calcitonin

Time frame:From Baseline (Week 0) to Week 104

Thyroid event

change from baseline, descriptive

Posted result

Group	Value (geometric_mean), nanogram per liter (ng/L)	95% CI
Semaglutide 2.4 mg	0.99	—
Placebo	0.97	—

Secondary/protocol endpoint

Number of Treatment-emergent Adverse Events (TEAEs)

Time frame:From Baseline (Week 0) to Week 111

Treatment-emergent AEs (any)

event count, event

Secondary/protocol endpoint

Number of Serious Adverse Events (SAEs)

Time frame:From Baseline (Week 0) to Week 111

Serious AEs (any)

event count, event

Secondary/protocol endpoint

Change From Baseline (Week 0) to Week 104 in Amylase

Time frame:From Baseline (Week 0) to Week 104

change from baseline, descriptive

Secondary/protocol endpoint

Change From Baseline (Week 0) to Week 104 in Lipase

Time frame:From Baseline (Week 0) to Week 104

change from baseline, descriptive

Secondary/protocol endpoint

Change From Baseline (Week 0) to Week 104 in Calcitonin

Time frame:From Baseline (Week 0) to Week 104

Thyroid event

change from baseline, descriptive

Publications (5)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Psychiatric Safety of Semaglutide for Weight Management in People Without Known Major Psychopathology: Post Hoc Analysis of the STEP 1, 2, 3, and 5 Trials.
JAMA internal medicine2024 Nov 1PMID39226070doi:10.1001/jamainternmed.2024.4346via clinicaltrials gov reference derived + pubmed nct search
Effect of semaglutide 2.4 mg once weekly on 10-year type 2 diabetes risk in adults with overweight or obesity.
Obesity (Silver Spring, Md.)2023 Sep (month)PMID37605636doi:10.1002/oby.23842via clinicaltrials gov reference derived + pubmed nct search
Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5.
Obesity (Silver Spring, Md.)2023 Mar (month)PMID36655300doi:10.1002/oby.23673via CT.gov background
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial.
Nature medicine2022 Oct (month)PMID36216945doi:10.1038/s41591-022-02026-4via clinicaltrials gov reference derived + pubmed nct search
Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5.
Obesity (Silver Spring, Md.)2020 Jun (month)PMID32441473doi:10.1002/oby.22794via CT.gov background + pubmed nct search

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableClinicalTrials.gov results section

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.